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Summary.-One hundred and thirty-nine untreated patients with acute myelogenous
leukaemia (AML) were admitted between August 1970 and December 1973 and
allocated into two remission treatment regimens: one to receive chemotherapy alone
and the other chemotherapy with immunotherapy. Of the patients who attained
remission, 22 were in the chemotherapy group and in September 1975 2 re-
mained alive, the median survival time being 270 days and after relapse 75 days.
Twenty-eight patients received immunotherapy during remission, and 5 re-
mained alive; the median survival time of the group being 510 days and after relapse
165days. Ongoingactuarialanalysispreciselypredictedearlyinthestudythemedian
survival ofthe two groups, but it took a2-yearfollow-up after entry ofthe last patient
before it became clear that there were very few long-term survivors. The increase
in survival time produced by the immunotherapy is apparently made up of two
components: prolongation of the first remission and length of survival after the first
relapse. It must be noted that the chemotherapy for this study was devised 6 years
ago and the results of the control arm (chemotherapy alone) may be poorer than
those obtained in contemporary studies.
IN AUGUST 1970 a study was initiated
to determine if BCG and leukaemia cells
could be used for the treatment ofpatients
with acute myelogenous leukaemia (AML)
during the remission phase of their
disease. The first analysis of the results
ofthis trial was published in 1973 (Powles
et al., 1973a) shortlybefore thelast patient
had been admitted to the study. It was
found that the patients who had received
immunotherapy plus intermittent chemo-
therapyduringremissionlivedsignificantly
longer than those who had received the
same chemotherapy alone. Moreover, at
thattime, life table analysis indicated that
immunotherapy produced a survival curve
that had a tail indicating that some of
these patients mighthave averyprolonged
survival. The data available in 1973 also
showed that the median length ofthe first
remission for patients receiving immuno-
therapy was prolonged by 66%, but
because of the variation in the remission
length within the two groups, the overall
difference was not statistically significant
at the 5% level. In this paper we report
the outcome of the follow-up of this trial
for a further period of 21 years. As the
trial was closed towards the end of 1973,
this means that all the patients have been
followed for at least 2 years. The histori-
cal background and scientific basis for this
study has already been described (Powles
et at., 1973a).
t Present position: CRC Professor of Medical Oncology, Southampton University.
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TREATMENT PROTOCOLS
Patient selection.-All patients with AML
who were first seen at St Bartholomew's
Hospital between 10 August 1970 and 31
December 1973 were included in the study.
Analysis was made of the data completed to
7 August 1975. Before any treatment was
given to induce remission, all patients were
allocated into one of two groups on an
alternate basis to determine whether they
would receive immunotherapy ifthey achiev-
edremission. Thetotal entryofnewpatients
was 139, 107 of whom were included in the
series described by Powles et al. (1973a), and
the rest were seen subsequently. The final
allocation of patients who attained full
remission was 22 to chemotherapy and 31
patients to chemo-immunotherapy. The two
groups do not have equal numbers because
they were allocated when they first entered
hospital, and the number in each group that
attained remission happened not to be the
same. Ofthe 31 patients allocated immuno-
therapy, 3 have not been included in the
analysis. One of these patients died of
infection after attaining full remission but
before immunotherapy was given; one patient
was 74 years old and could not tolerate the
repeated journey to and from the hospital,
and the third patient passed into remission
whilst receiving the immunotherapy, so it was
felt she was not representative of the group.
Inductiontreatment.-Theinductionproto-
col ofdrugs (fordetails seePowlesetal., 1973a)
consists of daunorubicin and cytosine ara-
binoside given in slightly modified ways
(Studies 2, 3, 4A and 4B-Crowther et at.,
1970, 1973). Fifty-three patients passed into
full remission, so that the overall remission
rate during the trial period now stands at
38%. All patients in remission in Studies 2,
3 and 4A received the identical maintenance
chemotherapy described by Powles et al.
(1973a), which consisted of 5-day courses of
cytosine arabinoside and daunorubicin alter-
nating with 5 days ofcytosine arabinoside and
6-thioguanine. Between every 5 days of
treatment there was a 23-day gap, and it was
during this period that patients received
immunotherapy. The patients in Study 4B
were all aged over 60 years, and their main-
tenance chemotherapy consisted of 3-day
courses every 2 weeks. All patients stopped
maintenance chemotherapy after one year (12
courses), and thereafter the chemo-immuno-
therapy patients received only immuno-
therapy and the chemotherapy patients
received no further treatment.
Immunotherapy.-Immunotherapy was
started whenever possible just before com-
plete remission, at a time when the marrow
was hypoplastic. In all instances, sub-
sequent marrow biopsies confirmed that these
patients had achieved a full remission. The
immunotherapy, described in detail previ-
ously (Powles et al., 1973a), consisted of
weekly BCG (Glaxo) and 109 irradiated allo-
geneic myeloblastic leukaemia cells given i.d.
and s.c., and timed to avoid the 5-day courses
of chemotherapy. All 4 limbs received the
BCG in turn, one weekly, and the cells were
injected into the other 3 limbs. The cells
were collected in a manner described previ-
ously (Powles et al., 1974) using an NCI/IBM
Blood Cell Separator and preserved in a
viable state at - 179°C in the presence of
DMSO (Powles et al., 1973b). Individual
patients received cells from the same donor
for as long as possible.
Treatment after relapse.-When patients
relapsed, the initial induction treatment with
daunorubicin and cytosine arabinoside was
repeated whenever possible. Ifno regression
of leukaemia was seen, the treatment was
usually changed to a combination of cyclo-
phosphamide and 6-thioguanine. If remis-
sionoccurred, themaintenance treatment was
modified to a single injection ofdaunorubicin
and 3 days of cytosine arabinoside followed
11 days later by 3 days of oral cyclophos-
phamide and 6-thioguanine. After another
11-daygapthe whole cycle wasrepeated, with
maintenance chemotherapy for 3 days every
fortnight. Those patients who previously
received immunotherapy were given further
treatment with BCG and a different popula-
tion of irradiated AML cells.
RESULTS
Tables I and II give the clinical details
at presentation, remission lengths and
survival time for each of the patients in
the two arms of the trial. At this time,
August 1975, 5/28 patients in the chemo-
immunotherapy arm remained alive, al-
though 4 of these had relapsed; 2/22
patients on chemotherapy were alive, both
still in their first remission. The actuarial
analysis of the duration of survival of
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TABLE I.-Clinical Details of Chemo-immunotherapy Patients
Sex
F
M
F
M
F
F
F
M
F
F
M
M
M
F
M
M
M
M
M
M
M
M
M
F
M
M
M
F
Age
52
49
29
14
44
52
50
34
23
39
23
55
52
58
42
37
26
25
56
20
59
23
57
30
23
68
61
66
Diagnosis
AML
AML
AMML
AMML
APML
AML
AMML
AML
AML
AMML
AML
AML
AMML
AMML
AML
AML
AML
AML
AMML
AML
AMML
AML
AML
AML
AMML
AML
EL
AML
Presenting
blood white
cell count
x 10./1
1.1
1*3
1.0
68*0
29-0
25-0
25*0
1.9
38*0
4*0
23-0
1*6
3*8
2*4
8-1
0*5
7-2
8*4
9.5
1-4
95.4
2-9
1*7
5-1
77*6
27-5
2*8
11.1
Remission
length
313
1648+
209
374
417
914
539
622
646
106
253
172
305
495
84
737
43
144
573
80
116
253
666
759
370
91
82
229
Days
Survived
from 1st
remission
546
1648±
300
533
462
1165
932
952
833
235
687
378
401
515
168
807
251
204
911+
124
280
619
752±
787+
821±
300
116
270
Survived
after
relapse
233
91
159
45
251
393
330
187
129
434
206
96
20
84
70
208
60
338+
44
164
366
86±
28+
451+
209
34
41
Acute myeloblastic leukaemia.
Acute myelomonocytic leukaemia.
Acute promyelocytic leukaemia.
Erythro-leukaemia.
these patients after attaining remission is
given in Fig. 1. The median duration of
survival ofthe chemotherapy group is 270
days, and that for the chemo-immuno-
therapy group 510 days. Statistical ana-
lysis of survival data calculated by the
" logrank " non-parametric method (Peto
and Pike, 1973) gives an overall chi-
squared for the differences between these
two groups of 4-48; P 0 0-03. One ofthe
3 immunotherapy patients excluded from
the analysis died in remission at Day 0,
prior to immunotherapy, and the other
2 patients remained alive at the time of
analysis at 465 and 655 days. Their
exclusion therefore does not materially
affect the analysis.
Fig. 2 shows the actuarial analysis for
the length of first remission; the median
durations being 305 days for the chemo-
immunotherapy group and 191 days for
the chemotherapy group. However, the
overall difference between the two groups
was not statistically significant at the 5%
level.
The actuarial analysis of the length of
survival after relapse for the two groups of
patients is shown in Fig. 3. The median
values are 75 days for the chemotherapy
patients and 165 days for the chemo-
immunotherapy patients, and the dif-
ference between the two groups has a very
high statistical significance (overall chi-
square 12-24; P - 0.0005). One-third
of the patients in the chemo-immuno-
therapy group achieved a second remis-
sion, and those who did not receive a full
second remission had a prolonged survival
when compared with the chemotherapy
controls.
Pt.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
AML
AMML
APML
EL
t
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TABLE II. Clinical Details ofPatients Receiving Chemotherapy Alone
Presenting
blood white
cell count
x 109/1
3-0
4-5
1*8
1-8
14-0
28-0
8-8
52-0
0-8
1-3
133.0
0-8
31-8
1*1
1*7
84-0
10-9
32-0
94 0
2-2
1-5
1-5
Days
Survivedl
Remission from 1st
length remission
348
119
188
217
326
377
211
180
129
81
76
143
1019+
468
659
191
72
48
885-
209
237
55
528
194
25'2'
403
376
491
293
:312
304
161
129
143
10(19 9
497
807
219
162
161
885+
261
273
93
Survived
after
relapse
180
75
64
186
50
114
82
1:32
175
80
53
0
29
148
28
90
113
52
36
38
DISCUSSION
Values and limitations ofactuarial analysis
of an on-going trial
The data from this studv were analysed
at 6-monthly intervals starting in May
1972) (i.e. 18 months after the trial was
initiated) and the survival of the chemo-
immunotherapy group was plotted as raw
data without actuarial correction (i.e.
fixed interval) in Fig. 4, and after actuarial
correction in Fig. 5. Only the actuarial
method predicted the median survival.
Thus, 6 months before the trial was com-
pleted (Curve 2, Fig. 5) at a time when
80% of the patients were still alive and
new patients were still being admitted, the
median was accurately predicted. How-
ever, it required another one year after
completion of the study (Curve 5, Fig. 5)
before it became certain, even with actu-
arial analysis, that the inclusion of im-
munotherapy in the treatment regime did
not lead to a significant deviation of the
survival curves from the constant risk
pattern in which all patients ultimately die
oftheir disease: i.e. the treatment had not
given rise to a sub-population of patients
Years
FIG. 1. Survival following remission of twro
groups ofpatients with A_IL (Bart's 2, 3, 4A
an(c 4B) allocate(d at presentation; one
group receiving maintenance chemotherapy
alone (C), the other group chemotherapy
plus immunotherapy (C +I). The percent-
age suirviving at (lifferent, times has beeix
calculated by standard actuarial methods.
The vertical (Irops show the times at which
individual patients died. 20/22 chemo-
therapy patients and 23/28 chemo-immuno-
therapy patients have dlied. Analysis of
follow-up to 7 August 1975. m = medlian
survival in days. Difference between curves
has P = 0-03.
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Pt.
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Sex
M
F
F
M
F
M
M
F
M
M
M
F F
M
M
M
M
M
M
M
Age
49
67
45
44
63
63
22
16
28
19
33
42
55
59
65
37
26
26
58
64
64
61
Diagnosis
AML
AML
EL
AML
AML
AMML
AMML
AMML
AML
AML
AML
AML
AMML
AML
AML
AML
AML
AML
AML
AML
AML
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.Cn
0
U'
C-
Years
FIG. 2.-Similar analysis to Fig. 1 of the
duration of first remission of the same
patients. 2/22 chemotherapy patients and
1/28 chemo-immunotherapy patients re-
main in first remission. The difference
in length of remission is non-significant.
who had become long-term survivors.
Initially the actuarially corrected curves
indicated a tail and the possibility oflong-
term survivors (Curves 3 and 4, Fig. 5). As
time went on, it became clear that the
fraction of patients in the tail progres-
sively decreased (Curves 6-8, Fig. 5). We
must now conclude that while immuno-
therapy increases the median length of
survival by approximately 90%, it does
not change the ultimate shape of the
survival curve, which is the same for both
treatment methods, and indicates that
fewer than 5% of patients with AML
treated by either ofthe two procedures in
this trial are going to be long-term
survivors. Currently (July 1976) only
1 chemo-immunotherapy and 2 chemo-
therapy patients remain alive. Thus,
while actuarial analysis reliably predicted
the median duration ofsurvival, it did not
showwhetherornotlong-termsurvivalwas
probable for a sub-population until long
after the study was completed.
Mechani8ms of prolongation of life by
immunotherapy
There is a high probability that adding
immunotherapytotheintermittentchemo-
therapy given as a maintenance treatment
during remission extended the length of
survival of patients in our study. Two
distinct components can contribute to this
effect: (1) prolongation ofthe length ofthe
first remission, and (2) extension of the
length of survival after relapse. The
present study did not allow us to decide
whether the length of the first remission
was extended by the immunotherapy,
because the 60% difference in the median
was not statistically secure. The inability
c+l
12
Months
Fia. 3.-Similar analysis to Fig. 1 ofthe duration ofsurvival after relapse of the relapse patients shown
in Fig. 2. Difference in survival has P = 00005.
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31
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L.
(n
'73)
4
8
1000
L Days
FIG. 4.-Sequential 6-monthly analysis ofthe duration ofsurvival (from diagnosis) ofthe 28 patients
receiving chemo-immunotherapy in Bart's 2, 3, 4A and 4B studies. The first analysis (Curve 1) was
in May 1972, Curve 3 (May 1973) corresponds to the entry of the last patient in the group, and
Curves 4 to 8 are analyses at 6-monthly intervals thereafter. Triangles denote patients remaining
alive and the curves drop each time a patient dies, by an amount proportional to the total number
ofpatients in the study.
a
L
(n
Days
FIG. 5.-The same patients have been analysed in the same way as in Fig. 4, except that the standard
actuarial method ofanalysis has been used. Each time apatient dies the curve drops by an amount
proportional to the number ofpatients who have reached and had the chance to die at that moment
in time.
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to resolve this aspect in this trial was due
to the wide variation in remission lengths
within each group, and this makes it
possible that the observed difference may
have arisen by chance, in view ofthe small
number of patients in each group. It is
therefore fruitless to speculate whether the
administration ofBCG and leukaemic cells
during remission has produced in patients
with AML an effect like that seen in experi-
mental animals, where similar therapies
heightened the capacity of the host to
contain residual malignant cells (Alex-
ander and Hall, 1970).
It is unlikely that prolongation of
survival after relapse was due to the
immunotherapy increasing the immune
reaction of the host against leukaemia-
specific antigens, and it seems more prob-
able that this effect was produced by
stimulation of the bone-marrow, which
permitted patients who had received
immunotherapy and who had then relap-
sed, to tolerate the high doses of cytotoxic
chemotherapy necessary to constrain the
disease. Such an effect has been seen in
animal systems (Wolmark, Levine and
Fisher, 1974; Dimitrov et al., 1975) and
cotuld be important, because patients who
relapse usually die from bone marrow
failure. The outcome of our study was
therefore disappointing, since we cannot
tell if we achieved an effect of specific
activeimmunotherapy. Furthermore, the
chemotherapy regime used for this study
was devised 6 years ago, and it is possible
that current studies using chemotherapy
alone may produce better survival results
than our control arm and not differ
significantly from our chemo-immuno-
therapy results.
A group in Manchester (Freeman et al.,
1973) followed the same immunotherapy
protocol as used here, and, whilst they did
not carry controls in their clinical trial,
they commented on the ease with which
patients who had received immunotherapy
without maintenance chemotherapy
achieved asecondremission, andalso noted
the long period ofsurvival after relapse in
this group.
Relative contribution of leukaemia cells and
of BCG in extending life after relapse
In many animal systems, the immuno-
therapeutic effect achieved by systemic
administration of BCG is much inferior to
that produced by inoculation of killed
tumour cells at multiple sites (Haddow
and Alexander, 1964; Parr, 1972). How-
ever, the two procedures given simultane-
ously were found in some animal situations
to act synergistically, and hence we intro-
duced the combined treatment ofBCG and
cells in this trial of immunotherapy. In
view of the animal data, we did not feel
justified in having an arm of treatment
which contained only BCG. Unexpec-
tedly, the treatment given as potential
immunotherapy prolonged life after re-
lapse, and we cannot resolve the question
of the relative contribution of BCG and
irradiated cellsinbringingaboutthis effect.
It is possible that both components may
contribute.
Vogler and Chan (1974) gave a pre-
liminary report of a trial in patients with
AML, in whom they noted a prolongation
of remission in the immunotherapy group.
However, a follow-up does not appear to
have been published, and no data are
available concerning the length ofsurvival
ofpatients who received BCG in remission.
Another investigation involving the use of
BCG in AML, which was essentially
similar to the trial reported by Vogler and
Chan, has been carried out by the Houston
group (Gutterman et al., 1974). While
they claim a distinct benefit from the use
of BCG in maintaining AML patients in
remission, criticism of the statistical
analysis and data in this study (Peto and
G-alton, 1975) must lead to reservations
concerning the significance ofthese conclu-
sions. More recently, a controlled study
by Leukaemia Group B in the U.S.A.
(Bekesi, Roboz and Holland, 1977) has
claimed that neuraminidase-treated AML
cells (with or without an extract of
tubercle bacillus MER) given to patients
receiving chemotherapy, has produced a
highly significant prolongation of remis-
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sion, when compared with patients with
chemotherapy alone. Time must elapse
before the significance of these three
studies can be fully appreciated, particu-
larly concerning the possibility of a group
of patients becoming long-term survivors.
CONCLUSION
It is obvious that this trial has raised
more questions than it has answered.
From a clinical point ofview it is useful, in
that it has shown that a relatively atrau-
matic type ofmaintenance treatment (i.e.,
BCG plus irradiated leukaemia cells)
extends the life of patients with AML,
though without curing a significant num-
ber of them. Further progress in the
treatment ofAML, by methods other than
the use of cytotoxic chemotherapeutic
agents, requires the measurement of the
reaction (if any) of the host against his
tumour, so that it can be determined
whether " immunotherapy " has a place in
the treatment of this disease. The first
requirement for such studies is to estab-
lish whether patients with AML are
capable of reacting to a macromolecule in
the membrane of their leukaemia cells,
and the subsequent paper constitutes our
approach to this problem.
We are indebted for support for this
study to the Leukaemia Research Fund,
the Imperial Cancer Research Fund, the
Joseph Frazer Strong Trust and the
Medical Research Council. We gratefully
acknowledge that the late Professor G.
Hamilton Fairley initiated this study.
The statistical analysis of this study was
performed by Dr Richard Peto of the
D.H.S.S. Cancer Epidemiology and Clini-
cal Trials Unit, Department ofthe Regius
Professor of Medicine, University of
Oxford, and we gratefully acknowledge his
help throughout the study and with the
preparation of this manuscript.
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